SCHEMBL5637199

SCHEMBL5637199

Clc1ccccc1-c1cc2c3c(c1)[C@H]1CNCC[C@H]1N3CCCS2

nearest known ligand 0.69

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 18/20 0.69
HTR2A P28223 16/20 0.62
HTR2B P41595 4/20 0.62
DRD2 P14416 11/20 0.36
HTR1A P08908 1/20 0.32
HTR1D P28221 1/20 0.32
HTR1B P28222 1/20 0.32
HTR1E P28566 1/20 0.32
HTR7 P34969 1/20 0.32
HTR3A P46098 1/20 0.32
HTR5A P47898 1/20 0.32
HTR6 P50406 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5637561 0.92 HTR2C (0.70) HTR2CHTR2AHTR2BDRD2
SCHEMBL5636211 0.92 HTR2C (0.70) HTR2CHTR2AHTR2BDRD2
SCHEMBL5636902 0.91 HTR2C (0.68) HTR2CHTR2AHTR2BDRD2
SCHEMBL5636191 0.89 HTR2C (0.66) HTR2CHTR2AHTR2BDRD2
SCHEMBL5636247 0.89 HTR2C (0.76) HTR2CHTR2AHTR2BDRD2
SCHEMBL255569 0.89 HTR2C (0.76) HTR2CHTR2AHTR2BDRD2
SCHEMBL5636558 0.89 HTR2C (0.80) HTR2CHTR2AHTR2BDRD2
SCHEMBL5635452 0.88 HTR2C (0.69) HTR2CHTR2AHTR2BDRD2HTR1A
SCHEMBL5637189 0.88 HTR2C (0.64) HTR2CHTR2AHTR2BDRD2
SCHEMBL5637598 0.88 HTR2C (0.69) HTR2CHTR2AHTR2BDRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE39679-E1 Substituted heterocycle fused gamma-carbolines BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2007-06-05 US disclosed
US-6713471-B1 SUCH AS TERT-BUTYL-1-METHYL-6,7,9,12-TETRAHYDRO-5H-PYRIDO-(4,3-B)(1,4) THIAZEPINO(2,3,4-HI)INDOLE-11(10H)-CARBOXYLATE; SEROTONIN AGONISTS AND ANTAGONISTS; CENTRAL NERVOUS SYSTEM DISORDERS BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-03-30 US disclosed